证券代码：688656 证券简称：浩欧博 公告编号：2025-013 江苏浩欧博生物医药股份有限公司 第三届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 1. 审议通过《关于<公司 2024 年年度报告>及其摘要的议案》 经审议，董事会认为：《公司 2024 年年度报告》及其摘要的编制和审核程序符 合相关法律法规及《公司章程》的有关规定，能够公允地反映公司报告期内的财务 状况和经营成果。董事会全体成员保证公司 2024 年年度报告披露的信息真实、准 确、完整，不存在任何虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、 准确性和完整性依法承担法律责任。 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）披露的《江苏浩 欧博生物医药股份有限公司 2024 年年度报告》及《江苏浩欧博生物医药股份有限 公司 2024 年年度报告摘要》。 本次董事会会议召开前，本议案已经公司董事会审计委员会审议通过。 表决情况：7 票同意，0 票反对，0 票弃权，同意的票数 ...

每股分配比例：每股派发现金红利 0.3 元（含税），不进行资本公积转增股本， 不送红股； 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购专用证 券账户中的股份数为基数，具体日期将在权益分派实施公告中明确； 在实施权益分派的股权登记日前公司总股本扣减公司回购专用证券账户中的 股份数发生变动的，拟维持每股分配比例不变，相应调整分配总额，并将另行公告具 体调整情况； 不会触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》（以下 简称"《科创板股票上市规则》"）第 12.9.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 证券代码：688656 证券简称：浩欧博 公告编号：2025-015 江苏浩欧博生物医药股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （二）是否可能触及其他风险警示情形 一、利润分配方案内容 （一）利润分配方案的具体内容 经立信会计师事务所（特殊普通合伙）审计，江苏浩欧博生物医药股份有限公司 （以下简称 ...

Financial Performance - The company's operating revenue for 2024 was CNY 402.34 million, representing a 2.01% increase compared to CNY 394.41 million in 2023[23]. - The net profit attributable to shareholders for 2024 decreased by 22.24% to CNY 36.80 million from CNY 47.33 million in 2023[23]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 35.88 million, down 17.16% from CNY 43.30 million in 2023[24]. - The company's cash flow from operating activities for 2024 was CNY 101.22 million, a decrease of 1.43% compared to CNY 102.69 million in 2023[24]. - Basic earnings per share for 2024 were CNY 0.59, down 21.33% from CNY 0.75 in 2023[25]. - The company's total assets increased by 8.80% to CNY 1,032.80 million at the end of 2024, compared to CNY 949.26 million at the end of 2023[24]. - The company's net assets attributable to shareholders increased by 0.17% to CNY 812.14 million at the end of 2024, compared to CNY 810.73 million at the end of 2023[24]. - The company's overall operating revenue increased by 2.01% despite a challenging economic environment, driven by strong sales in allergy and autoimmune testing product lines[33]. - Net profit decreased by 22.24% year-on-year, primarily due to significant increases in costs associated with new business investments, particularly in desensitization drugs[33]. Dividend Distribution - The company plans to distribute a cash dividend of 3.0 RMB per 10 shares, totaling approximately 18.68 million RMB, which represents 50.75% of the net profit attributable to shareholders for the fiscal year 2024[6]. - In 2023, the company distributed a cash dividend of RMB 0.40 per share, amounting to RMB 24.90 million, which accounted for 52.61% of the net profit attributable to shareholders[174]. - The cumulative cash dividend over the last three accounting years was RMB 62.50 million, with an average net profit of RMB 41.93 million, resulting in a cash dividend ratio of 149.06%[180]. Research and Development - Research and development expenses accounted for 11.50% of operating revenue in 2024, a decrease of 0.42 percentage points from 11.92% in 2023[25]. - The total R&D investment for the year was CNY 4,626.90 million, representing 11.50% of total revenue, a decrease of 0.42 percentage points from the previous year[73]. - The company has established a standardized research program for natural allergen raw materials to ensure batch consistency[69]. - The company has successfully developed core technology platforms for recombinant antigen expression and purification, ensuring consistency in raw materials across different batches[69]. - The company has applied for 8 invention patents and obtained 2, bringing the total number of invention patents to 107[71]. - The company is focusing on enhancing its core technology capabilities with a dedicated team of technical personnel[147]. - The company has made significant investments in research and development to enhance its product offerings in the biopharmaceutical sector[130]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, including collaborations and licensing agreements to enhance product offerings[14]. - The company is exploring new technologies in immunoassay methods to improve diagnostic accuracy and efficiency[13]. - The company is actively pursuing international market expansion by developing products suitable for global markets and establishing international marketing teams[134]. - The company aims to consolidate and expand its market share in allergy testing by leveraging its diverse product offerings and high-quality services[134]. - The company is positioned to capitalize on the domestic market's shift towards local alternatives to imported products, enhancing its competitive edge[61]. - The company is expanding its product menu with 35 allergen projects, including 3 mixed allergens and 10 component allergens, with a total investment of $1,707.00 million and $188.43 million invested in the current period[77]. Product Development and Innovation - The company focuses on in vitro diagnostic reagents, kits, and quality control products for various human samples[12]. - The product lines include enzyme-linked immunoassay products, capturing method products, and chemiluminescence products, enhancing sensitivity and speed in testing[13]. - The company has introduced a series of desensitization products under the brand "欧脱克," covering 17 allergens[14]. - The company has developed a comprehensive product menu in the allergy and autoimmune testing fields, effectively breaking the monopoly of imported products[57]. - The company has launched a total of 56 allergen-specific IgE antibody test kits, including tests for total IgE and common food allergens[44]. - The company’s self-immune product line includes 51 different detection items, focusing on specific antibody testing for various autoimmune diseases[46]. - The company aims to replace high-priced imported enzyme-linked immunosorbent assay products with its own chemiluminescence products in the self-immune testing field[46]. Operational Efficiency - The company has upgraded 8 automated production lines to enhance smart manufacturing capabilities, improving efficiency and product quality while reducing labor costs[37]. - The production strategy is based on "sales-driven production" to maintain safety stock levels, with production plans adjusted according to sales forecasts[49]. - The company has established a systematic supplier management mechanism to ensure the stability and quality of its supply chain[47]. - The company emphasizes a strict quality management system, adhering to ISO13485 standards and ensuring full-process quality control from raw material inspection to finished product testing[38]. Risks and Challenges - The company faces risks related to new product development and registration, which typically require over a year for completion, impacting future profitability if not successfully executed[88]. - There is a risk of core technology leakage and loss of key personnel, which could undermine the company's competitive advantage in the market[88]. - The company faces risks related to the potential exclusion of food-specific IgG testing products from medical insurance directories, which could adversely affect sales[91]. - The market for food-specific IgG testing products is limited due to academic controversies, posing a risk to future revenue[91]. - The company is navigating challenges in promoting its new Otuoke series products, which currently can only be sold in designated areas, potentially limiting sales growth[89]. Corporate Governance - The board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures for providing guarantees[8]. - The company has not reported any special arrangements in corporate governance[8]. - The company has established a comprehensive quality management system, ensuring no major product quality issues or disputes during the reporting period[39]. Environmental, Social, and Governance (ESG) - The company emphasizes the integration of ESG principles into its operational management, aiming for sustainable and high-quality development[193]. - The company invested ¥87.76 million in environmental protection measures during the reporting period[196]. - The company is classified as a key pollutant discharge unit and has obtained the necessary discharge permits[197]. - Wastewater generated from production is treated in the company's self-built wastewater treatment station before being discharged into the municipal sewage system[198]. - The company collaborates with qualified third-party waste disposal companies to manage hazardous waste effectively[198].

Financial Performance - Total revenue for 2024 reached RMB 402.31 million, a 2.00% increase compared to RMB 394.41 million in the previous year[3] - Operating profit decreased by 25.88% to RMB 41.39 million from RMB 55.84 million year-on-year[3] - Net profit attributable to shareholders decreased by 22.15% to RMB 36.85 million from RMB 47.33 million in the previous year[3] - Basic earnings per share decreased by 21.33% to RMB 0.59 from RMB 0.75 in the previous year[3] Assets and Equity - Total assets increased by 8.77% to RMB 1,032.50 million from RMB 949.26 million at the beginning of the period[3] - The company's equity attributable to shareholders increased by 0.18% to RMB 812.18 million from RMB 810.73 million at the beginning of the period[3] Business Strategy - The company plans to continue strengthening its main business in allergy and autoimmune diagnostics, with increased investment in new product development and technology[8] - The company aims to optimize supply chain management and enhance cost efficiency to improve core competitiveness and profitability[9] Non-Operating Income - The increase in non-operating income was affected by reduced returns from bank financial products compared to the previous year[10] Financial Reporting - The financial data presented is preliminary and subject to change upon final audit in the annual report[11]

| 粒化学发光法) | （IF）抗体。临床上主要用 | | --- | --- | | | 于自身免疫性萎缩性胃炎 | | | 及恶性贫血的辅助诊断。 | 二、 对公司的影响 重要内容提示： 江苏浩欧博生物医药股份有限公司（以下简称"公司"）全资子公司湖南浩欧 博生物医药有限公司于近日获得湖南省药品监督管理局核准签发的 4 项医疗器 械注册证，现将有关情况公告如下： 序号 注册人 名称 产品名称 注册证编号 有效期至 预期用途 1 湖南浩欧 博生物医 药有限公 司 抗黑色素瘤分化 相关基因 5 抗体检 测试剂盒(磁微粒 化学发光法) 湘械注准 20252400138 2030-1-23 本试剂盒用于体外定性检 测人血清样本中抗黑色素 瘤分化相关基因5抗体，临 床上主要用于皮肌炎和间 质性肺病的辅助诊断。 2 抗胃壁细胞(PCA) 抗体检测试剂盒 (磁微粒化学发光 法) 湘械注准 20252400187 2030-2-19 本试剂盒用于体外定性检 测人血清样本中人抗胃壁 细胞（PCA）抗体。临床上 主要用于恶性贫血（维生素 B12缺乏）和萎缩性胃炎的 辅助诊断。 3 抗C1q抗体检测试 剂盒(磁微粒化学 发光法 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-010 江苏浩欧博生物医药股份有限公司 关于双润正安信息咨询（北京）有限公司要约收购公司股份 交割完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏浩欧博生物医药股份有限公司（以下简称"浩欧博"）于 2024 年 12 月 20 日披露了《江苏浩欧博生物医药股份有限公司要约收购报告书》，双润正安信息咨 询（北京）有限公司（以下简称"双润正安"或"收购人"）向除收购人及其一致 行动人以外的浩欧博全体股东发出部分要约，预定要约收购股份数量为 15,570,480 股，占剔除回购专用账户中股份数量后浩欧博股份总数的 25.01%，要约收购价格为 33.74 元/股，要约收购期限为 2024 年 12 月 24 日至 2025 年 1 月 22 日。 截至 2025 年 1 月 22 日，本次要约收购期限届满。根据中国证券登记结算有限 责任公司上海分公司（以下简称"中登公司上海分公司"）提供的数据统计，本次 要约收购期限内，预受要约的股东账户总数为 5 户 ...

根据中国证券监督管理委员会于 2020 年 12 月 15 日出具的《关于同意江苏浩 欧博生物医药股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕3415 号），公司获准向社会公开发行人民币普通股 1,576.4582 万股，每股发行价格为人 民币 35.26 元，募集资金总额为人民币 55,585.92 万元；扣除发行费用后实际募集 资金净额为人民币 49,646.58 万元。上述资金已全部到位，立信会计师事务所（特 殊普通合伙）对公司本次公开发行新股的资金到位情况进行了审验，并于 2021 年 1 月 8 日出具了信会师报字[2021]第 ZA10021 号《验资报告》。 证券代码：688656 证券简称：浩欧博 公告编号：2025-009 江苏浩欧博生物医药股份有限公司 关于注销闲置募集资金理财账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏浩欧博生物医药股份有限公司（以下简称"公司"）于近日完成了闲置募 集资金理财账户的注销手续，现将有关事项公告如下： 一、募集资金基本情况 江苏浩欧博 ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-008 本次要约收购完成后，双润正安持有浩欧博 14,326,151 股股份，占剔除回购 专用账户中股份数量后浩欧博股份总数的 23.01130%，双润正安及其一致行动人共 计持有浩欧博 32,997,029 股股份，占剔除回购专用账户中股份数量后浩欧博股份 总数的 53.00130%。根据《中华人民共和国证券法》《上海证券交易所科创板股票 上市规则》等相关规定，公司股权分布仍符合上市条件，上市地位不受影响。 1 双润正安按照上海证券交易所和中登公司上海分公司的有关规定履行了相关 义务，本次要约收购清算过户手续将于近日办理。 公司将根据有关规定及时履行信息披露义务，敬请广大投资者理性投资，注意 投资风险。 特此公告。 江苏浩欧博生物医药股份有限公司 关于双润正安信息咨询（北京）有限公司要约收购公司股份 的清算公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏浩欧博生物医药股份有限公司（以下简称"公司"或"浩欧博"）于 2024 年 12 月 20 日披露 ...

重要内容提示： 证券停复牌情况：适用 因双润正安信息咨询（北京）有限公司（以下简称"双润正安"或"收购人"） 要约收购江苏浩欧博生物医药股份有限公司（以下简称"公司"、"浩欧博"或"上 市公司"）股份事项,本公司的相关证券停复牌情况如下： | 证券代 | 证券简称 | 停复牌类型 | | 停牌起始日 | 停牌 | 停牌终止 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 码 | | | | | 期间 | 日 | | | 688656 | 浩欧博 | A 股 | 复牌 | 2025/1/23 | 全天 | 2025/1/23 | 2025/1/24 | 证券代码：688656 证券简称：浩欧博 公告编号：2025-007 江苏浩欧博生物医药股份有限公司 关于双润正安信息咨询（北京）有限公司要约收购结果 暨股票复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次要约收购期限内，预受要约的股东账户总数为 5 户，预受要约股份总数为 14,326, ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-006 江苏浩欧博生物医药股份有限公司 关于双润正安信息咨询（北京）有限公司要约收购期满 暨股票停牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 规定及时履行信息披露义务，敬请广大投资者关注公司后续公告并注意投资风险。 特此公告。 江苏浩欧博生物医药股份有限公司董事会 2025 年 1 月 23 日 因双润正安信息咨询（北京）有限公司（以下简称"双润正安"或"收购人"） 要约收购江苏浩欧博生物医药股份有限公司（以下简称"公司"或"浩欧博"）股 份事项,本公司的相关证券停复牌情况如下： | 证券代 | 证券简称 | 停复牌类型 | | 停牌起始日 | 停牌 | 停牌终止 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 码 | | | | | 期间 | 日 | | | 688656 | 浩欧博 | A 股 | 停牌 | 2025/1/23 | 全天 | 2025/1/2 ...